Merit Medical Systems, Inc. filed a Form 8-K on October 29, 2026, disclosing its third-quarter 2026 operating and financial results and announcing the acquisition of Solo Pace, Inc. for approximately $45 million in cash.

Key Highlights

  • Acquisition completed: Merit acquired Solo Pace, Inc. on October 13, 2026, pursuant to a Stock Purchase Agreement.
  • Purchase price: Merit paid cash of approximately $45 million to acquire the outstanding equity interests of Solo Pace.
  • Strategic rationale stated: The acquisition is described as "Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology," according to the accompanying press release title.
  • Q3 2026 results announced: A press release reporting third-quarter results for the quarter ended September 30, 2026, was furnished as Exhibit 99.1.
  • Revenue growth highlighted: The earnings press release is titled "Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance."
  • Non-GAAP disclosures included: The filing notes that Merit is disclosing non-GAAP financial information alongside GAAP results, with reconciliations included in the press release and conference call presentation.

Merit Medical Reports Q3 2026 Results and Closes Solo Pace Acquisition

Merit Medical Systems, Inc. (NASDAQ:MMSI) filed a current report on October 29, 2026, covering two separate disclosures: its financial results for the quarter ended September 30, 2026, and the completed acquisition of Solo Pace, Inc. The filing was signed by Brian G. Lloyd, Chief Legal Officer and Corporate Secretary.

According to the filing, Merit acquired Solo Pace on October 13, 2026, under a Stock Purchase Agreement, paying approximately $45 million in cash for the outstanding equity interests of the company. The accompanying acquisition press release, furnished as Exhibit 99.3, describes Solo Pace as bringing "Innovative TAVR Pacing Technology" to Merit's cardiac therapies platform, as stated in the press release title disclosed in the filing's exhibit list.

Separately, the filing furnishes an earnings press release as Exhibit 99.1, the title of which references "9% Organic Constant Currency Revenue Growth" for the third quarter and states that Merit "Raises Full-Year 2026 Guidance." The filing also notes that Merit conducted a conference call on October 29, 2026, with a live webcast and presentation available at merit.com, furnished as Exhibit 99.2. The filing discloses that Merit does not provide GAAP guidance reconciliations for forward-looking non-GAAP financial measures (other than revenue), citing an inability to predict with reasonable certainty items such as acquisition-related expenses, non-cash amortization, severance, and litigation-related costs.

What Was Disclosed

Merit Medical filed an 8-K on October 29, 2026, furnishing its Q3 2026 earnings press release, a conference call presentation, and a press release announcing its approximately $45 million cash acquisition of Solo Pace, Inc., which closed on October 13, 2026.